

## Nepal Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Nepal					
<b>2. Grant number(s):</b> 1821-NPL-12a-X; 14-NPL-08c-Y; 18-NPL-25a-Y					
<b>3. Date of Decision Letter:</b> 27 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 22 August 2014					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 4 doses per vial , LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2014 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)					
	2014-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	31,390,850 <sup>3</sup>	4,399,500	5,180,500	5,192,000	46,162,850
<b>10. Vaccine introduction grant (in US\$):</b>					
2014					
551,000 disbursed on 26 February 2014					
<b>11. Product switch grant (in US\$):</b>					
2018					
160,636 disbursed on 29 May and 6 June 2018					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2014-2018	2019			
Number of Pneumococcal vaccines doses		1,275,200			
Annual Amounts (US\$)	31,390,850 <sup>5</sup>	4,399,500			
<b>13. Procurement agency:</b> UNICEF					
Country shall release its co-financing payments each year to UNICEF.					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>14. Self-procurement:</b> Not applicable			
<b>15. Co-financing obligations:</b> Reference code: 1821-NPL-12a-X-C According to the co-financing policy, Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	88,800	145,600	146,000
Value of vaccine doses (US\$)	270,575	399,470	400,432
Total co-financing payments (US\$) (including freight)	273,000	403,500	404,000
<b>16. Operational support for campaigns:</b> Not applicable			
<b>17. Additional reporting requirements:</b>			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019 15 May 2019		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		
<b>18. Financial clarifications:</b> Not applicable			
<b>19. Other conditions:</b> Not applicable			

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
27 March 2019